ELIOS Announces New Research Results Visit our Press Room →

Personalized therapeutic cancer vaccine

From any solid tumor, for any patient, administered safely in any clinical setting.

“This is a treatment that is easy to use and my patients love the idea of using their own cells to treat their cancer.”

Elios Site Investigator

Personalized Therapeutic Cancer Vaccine ›

TLPLDC: Tumor Lysate, Particle-loaded, Dendritic Cell

Clinical Experience ›

Two decades of clinical development of the Elios therapeutic cancer vaccine

Our Vision

Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product, TLPLDC, is a personalized therapeutic cancer vaccine designed to attack cancer cells by igniting innate and adaptive immune responses which increase a patient’s own production of T cells to fight their specific cancer.

There remains a need for effective adjuvant treatments for high risk, resectable melanoma

A significant proportion of late-stage melanoma patients will ultimately experience a poor prognoses

Our Accomplishments

Elios by the numbers:

Ongoing and planned clinical trials
Patients in the Phase 2b randomized trial Monotherapy
Patients in the bridging trial Comparing two generations of Elios technology
Patients in the combination trial TLPLDC in combination with CPIs
Patients with preliminary data from the basket trial 14 different tumor types
Unblinded patients on adjuvant trial open-label arm

Proposed areas of research

ELIOS is developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types:

ELIOS Leadership

With our novel approach to the development of safe and efficacious therapeutic cancer vaccines, Elios is poised to realize the power of personalized medicine and transform how we treat cancer.

Buddy Long
Chief Executive Officer
  • BA: Winthrop University
  • US Marine Corps, Infantry Officer, Entrepreneur
George Peoples, MD, FACS
Chief Medical Officer
  • BS: US Military Academy – West Point
  • MD: Johns Hopkins University School of Medicine
  • Residency: Harvard’s Brigham & Women’s Hospital
  • Fellowship: MD Anderson Cancer Center
Thomas Wagner, PhD
Chief Scientific Officer
  • BA: Princeton University
  • PhD: Northwestern University

Partnerships and Opportunities

Contact us to learn more about our company and how we are advancing the promise of personalized therapeutic cancer vaccines to improve the lives of people with cancer around the world.

Contact us